Corvus Starts Phase 3 Trial in Relapsed/Refractory Peripheral T-Cell Lymphoma

 Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases

There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA

https://www.globenewswire.com/news-release/2024/09/10/2943658/0/en/Corvus-Pharmaceuticals-Initiates-Registrational-Phase-3-Clinical-Trial-of-Soquelitinib-for-Patients-with-Relapsed-Refractory-Peripheral-T-Cell-Lymphoma.html